"Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe ...

Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to ...

leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...

This edit results in the production of high levels of fetal hemoglobin (HbF ... from the cell surface to improve the persistence of the CAR T cells in an “off-the-shelf” setting.

leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...

leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...

The treatment also increased total hemoglobin levels and was well tolerated ... to introduce genetic changes that mimic those naturally found in people with hereditary persistence of fetal hemoglobin, ...

All four patients experienced rapid and robust fetal hemoglobin (HbF) induction by Month 1 (>60%) and corresponding sickle hemoglobin (HbS) reduction (≤36%) in non-transfused blood, which was ...

leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...

Those people have what is called hereditary persistence of fetal hemoglobin, something that all infants have, though most people’s blood switches over to adult hemoglobin at around 6 months old.